Amibegron hydrochloride: Clinical Trials

12 completed, 2 terminated. 14 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	14	Completed 12, Terminated 2

Follow Amibegron hydrochloride: new trials by email Literature Review of Amibegron hydrochloride trials Research Report on Amibegron hydrochloride

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder SR58611A - Anxiety Disorders	Phase 3	Terminated	Sanofi	55	2007-03-01	2009-03-12
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder SR58611A, escitalopram, placebo - Major Depressive Disorder	Phase 3	Completed	Sanofi	510	2007-01-01	2009-03-25
Prevention of Relapse Study of SR58611A in Improved Patients With Generalized Anxiety Disorder SR58611A - Anxiety Disorders	Phase 3	Terminated	Sanofi	257	2006-11-01	2009-03-12
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS) amibegron (SR58611A) - Major Depressive Disorder	Phase 3	Completed	Sanofi	680	2006-09-01	2009-03-25
A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder SR58611A - Depressive Disorder, Major Depression	Phase 3	Completed	Sanofi	704	2006-05-01	2009-03-12
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Depression SR58611A - Depressive Disorder	Phase 3	Completed	Sanofi	288	2006-04-01	2009-03-12
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder SR58611A - Anxiety Disorders	Phase 3	Completed	Sanofi	508	2006-03-01	2009-03-09
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder SR58611A - Anxiety Disorders	Phase 3	Completed	Sanofi	366	2005-12-01	2009-03-12
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder SR58611A - Major Depressive Disorder	Phase 3	Completed	Sanofi	476	2005-09-01	2009-03-12
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder amibegron (SR58611A) - Major Depressive Disorders	Phase 3	Completed	Sanofi	527	2005-09-01	2009-03-25
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder SR58611A - Major Depressive Disorder	Phase 3	Completed	Sanofi	468	2005-09-01	2009-03-12
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder SR58611A - Anxiety Disorder	Phase 3	Completed	Sanofi	360	2005-09-01	2009-03-12
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine amibegron (SR58611A), placebo, paroxetine - Major Depressive Disorders	Phase 3	Completed	Sanofi	317	2003-11-01	2009-03-25
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine amibegron (SR58611A), placebo, paroxetine - Major Depressive Disorders	Phase 3	Completed	Sanofi	306	2003-09-01	2009-03-25

Conditions studied

Depression (8)  ·  Depressive Disorder, Major (8)  ·  Anxiety Disorders (5)  ·  Depressive Disorder (3)  ·  Mental Disorders (1)  ·  Mood Disorders (1)

Sponsors

Sanofi (14)

Countries

France (5)  ·  United States (5)  ·  Bulgaria (4)  ·  Croatia (4)  ·  Finland (4)  ·  Russia (4)  ·  Serbia (4)  ·  Argentina (3)  ·  Czechia (3)  ·  Estonia (3)  ·  Romania (3)  ·  Slovakia (3)  ·  South Africa (3)  ·  Austria (2)  ·  Canada (2)